Hodgkin Lymphoma News and Research

RSS

Genentech releases Phase III PRIMA study findings

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan.

17 Sep 2009

Phase III EXTEND trial results of pixantrone announced

Cell Therapeutics, Inc. (CTI) today released updated 18-month follow-up clinical data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment.

16 Sep 2009

Phase II VICTOR-E1 clinical study results reported

Schering-Plough Corporation today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients.

15 Sep 2009

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.

15 Sep 2009

Zevalin radioimmunotherapy drug approved for treating non-Hodgkin's lymphoma

SNM applauds the U.S. Food and Drug Administration's (FDA) recent decision to approve the radioimmunotherapy (RIT) drug, Zevalin, as a front-line treatment of non-Hodgkin's lymphoma (NHL).

11 Sep 2009

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma AG, Germany. The milestone was triggered by Bayer’s submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for MN-IC, an ADC for solid tumors.

9 Sep 2009

Large B-cell non-Hodgkin's lymphoma now treatable

Cases of non-Hodgkin lymphoma have more than tripled in the last thirty years according to the latest Cancer Research UK figures published today.

8 Sep 2009

FDA notifies PDUFA action date for Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

5 Sep 2009

Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin’s Lymphoma

Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.

5 Sep 2009

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

NOXXON Pharma AG (NOXXON), clinical-stage developer of L-RNA based scaffolds (Spiegelmers®) that bind their targets conceptually similar to antibodies, announced today that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF) under the ministry’s small and medium enterprise innovation initiative (“KMU-Innovativ”).

3 Sep 2009

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.

3 Sep 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).

28 Aug 2009

Report suggests that exposure to cellphone radiation causes brain tumors

“Cellphones and Brain Tumors: 15 Reasons for Concern, Science, Spin and the Truth Behind Interphone,” was released today by a collaborative of international EMF activists. Groups affiliated with the report include Powerwatch and the Radiation Research Trust in the U.K., and in the U.S., EMR Policy Institute, ElectromagenticHealth.org and The Peoples Initiative Foundation. Download the report.

26 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Study reveals factors associated with higher mortality rate in haematological malignancy

A study of 7,689 admissions from 178 adult intensive care unit s in England, Wales and Northern Ireland has revealed the factors associated with a higher mortality rate in haematological malignancy. Researchers writing in BioMed Central's open access journal Critical Care found that certain factors have a significant impact on the risk of death.

25 Aug 2009

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

24 Aug 2009

Recently diagnosed young adults with blood-related cancers have better long-term survival rates

A new analysis has found that adolescents and young adults who were recently diagnosed with blood-related cancers have better long-term survival rates than those who were diagnosed in the 1980s. Published in the November 1, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that significant advances have been made in the treatment of 15 to 24 year-olds with leukemias and lymphomas; however, survival rates in this age group are still lower than those seen in younger children.

24 Aug 2009

Scientific advancement in treating blood-related cancers leads to better survival rates

A recent analysis has found that adolescents and young adults who were recently diagnosed with blood-related cancers have better long-term survival rates than those who were diagnosed in the 1980s.

24 Aug 2009

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Gloucester Pharmaceuticals will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC) meeting on September 2, 2009.

18 Aug 2009

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors.

11 Aug 2009

Hodgkin Lymphoma News and Research

Genentech releases Phase III PRIMA study findings

Phase III EXTEND trial results of pixantrone announced

Phase II VICTOR-E1 clinical study results reported

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Zevalin radioimmunotherapy drug approved for treating non-Hodgkin's lymphoma

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Large B-cell non-Hodgkin's lymphoma now treatable

FDA notifies PDUFA action date for Cell Therapeutics' NDA for pixantrone

Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin’s Lymphoma

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Report suggests that exposure to cellphone radiation causes brain tumors

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Study reveals factors associated with higher mortality rate in haematological malignancy

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Recently diagnosed young adults with blood-related cancers have better long-term survival rates

Scientific advancement in treating blood-related cancers leads to better survival rates

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News